Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 459 across all filing types
Latest filing 2024-12-04 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 85% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) reporting changes in issued shares or treasury shares and detailing on‐market share repurchases. It is not announcing an external report but constitutes the issuer’s own transaction disclosure. This falls squarely under “Transaction in Own Shares” (share buybacks/repurchases).
2024-12-04 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2024
Regulatory Filings Classification · 90% confidence The document is a HKEX monthly return under Chapter 19B detailing movements in share capital, issued shares, treasury shares, share options, warrants and repurchases for the month ended 30 November 2024. It is a routine regulatory submission to the exchange and does not constitute an annual or interim report, earnings release, management report, or specific transaction announcement. It falls under general regulatory filings that do not fit other specific categories.
2024-12-04 English
VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE SECOND PHASE III CLINICAL TRIAL OF OT-301 IN CHINA
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement by a Hong Kong-listed company providing a business update on clinical trial enrollment. It does not report financial results, board changes, dividends, capital actions, proxy materials, or any other specific category. It is not the publication of a formal report but rather a general regulatory announcement. Therefore, it falls under the fallback category for miscellaneous regulatory filings (RNS).
2024-12-03 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Next Day Disclosure Return (Form FF305) under the Hong Kong Stock Exchange Listing Rules detailing changes in issued shares, treasury shares, repurchases of shares, and on-market sale of treasury shares. It is a regulatory disclosure of the company’s own share transactions (buybacks and treasury share movements), matching the definition of Transaction in Own Shares (Code: POS).
2024-12-02 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) reporting changes in issued shares, treasury shares, and share repurchases (on‐market and for treasury) under Main Board/GEM Rules. It provides detailed tables of repurchase dates, prices, quantities, opening/closing balances, and confirmation statements. This is not an AGM announcement, earnings release, or annual report, but a statutory report of transactions in the company’s own shares. It matches the “Transaction in Own Shares” category.
2024-11-29 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Hong Kong Exchange “Next Day Disclosure Return” (Form FF305) detailing changes in issued shares and treasury shares, specifically reporting share repurchases (own shares transactions). It is not an earnings, annual, or management report, nor a simple announcement of an upcoming report. It directly discloses on‐market repurchases and treasury share movements, matching the definition of a Transaction in Own Shares (POS).
2024-11-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.